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Abstract
   Aim:  to understand the 2’-nitroimidazole induced hypoxia and liver  cell  interaction,  we 
proposed  a  “Hapatocellular  Hypoxia  Criteria”.  Hypothesis: The  nitroimidazole  induced 
metabolic energy loss and oxygen depletion (hypoxia) in liver cell  mitochondria  causes the 
phagocytosis.  Based on it, ten control subjects with 2’-nitroimidazole therapy were studied for 
their carbohydrate metabolizing enzymes in serum and hepatocellular enzymes in liver biopsy 
tissues.   Materials  and  Methods: Proven  ten  control  subjects  were  studied  for  hypoxia  by 
enzyme assays.  The 2’nitroimidazole treated paired ten subjects were studied for hypoxia using 
enzyme  assays  and  hepatocellular  cytomorphology  by  electron  microscopy.  Results  and  
Discussion: Out  of  ten  subjects  on  2’-nitroimidazole,  nine  showed  elevated  carbohydrate 
metabolizing  and  lysosomal  enzyme  levels  in  serum.  The  enzymes  glucokinase  (in  80% 
samples),  aldolase  (in  80%  samples),  phosphofructokinase  (in  80%  samples),  malate 
dehydrogenase  (in  75% samples),  isocitrate  dehydrogenase  (ICDH) (in  60% patients)  were 
elevated  while  succinate  dehydrogenase  and  lactate  dehydrogenase  (LDH)  levels  remained 
unaltered.    Lysosomal  enzymes  -glucuronidase,  alkaline  phosphatase,  acid  phosphatase,β  
showed enhanced levels in the serum samples.  In control ten liver biopsies, the hepatocytes and 
Kupffer  cell  preparations  showed  altered  enzyme  levels.   Hepatocytes  showed  lowered 
glucokinase (in 80%), LDH (in 80%), and higher content of aldolase (in 80%), pyruvate kinase 
(in 100%), malate dehydrogenase (in 80%), ICDH (in 80%), citrate dehydrogenase (in 70%), 
phosphogluconate dehydrogenase (in 80%).  Kupffer cells showed higher enzyme levels of -β
glucuroronidase (in 80%), leucine aminopeptidase (in 70%), acid phosphatase (in 80%) and aryl 
sulphatase (in 88%).  In these 10 biopsy samples from subjects on 2’-nitronidazole clinical trial, 
the electron microscopy cytomorphology observations showed swollen bizarre mitochondria, 
proliferative endoplasmic reticulum, and anisonucleosis after 2’-Nitroimidazole effect in liver 
cell damage.  Conclusion: The proposed “Hepatocellular Hypoxia Criteria” served to define 
origin of liver hypoxia and showed altered hepatic enzyme activities with active phagocytosis 
and cytotoxicity in subjects after 2’-nitroimidazole treatment. The study suggests the enzyme 
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based evaluation of nitroimidazole induced hypoxia monitoring and treatment of hepatic tumors 
and infected liver. 
Key  Words: liver,  enzymes,  electron  microscopy,  carbohydrate  metabolizing  enzymes,  
hepatocellular dysfunction criteria
Introduction
   2’nitroimidazole derivatives were considered drug of choice in treatment of hepatic hypoxia 
(low oxygen) conditions in parasitic infections, cancer and recently nitroimidazole derivatives 
are emerging as hypoxia markers and radiosensitizers in tumor treatment [1, 2].  Several reports 
on first  initial stage of nitroimidazole induced liver cell cytotoxicity indicated the apoptosis, 
glutathione,  DNA  interaction,  oxygen  depletion,  lactate  inhibition,  enhanced  NADPH 
cytochrome reductase and superoxide dismutase enzymes [3-15]. Still nitroimidazole structure-
function  relationship  of  hypoxia,  radiosensitization  and cytotoxicity  remain  less  understood 
perhaps due to its low sensitivity to clinical investigations and available enzyme alterations at 
the  very  late  necrotic  stage  [16-24].   However,  nitroimidazole  cytotoxicity  was  reported 
continuously  in  last  three  decades  indicating  altered  enzymes,  nitric  oxide  production, 
cytokines, oxygen depletion (hypoxia) and immunoactive substance release from both hepatic 
infections and cancer tumor tissues [25-30].  Still, studies do not establish the acceptability of 
growing  popularity  of  nitroimidazole  in  tumor  monitoring  and  treatment  as  risk  free  if 
nitroimidazole can induce tissue regeneration after hepatic infections or oxygen starved tumors 
[32]. The present report puts evidence of hepatic metabolic integrity loss (in mitochondria and 
cytoplasm)  and  lysosomal  stimulation  associated  with  hypoxia.  The  enzyme  based  routine 
evaluation of nitroimidazole or its derivatives is proposed to measure induced oxygen depletion 
and energy loss. The approach is applicable possibly in oxygen starved tumor cells or infected 
liver lesions and abscesses.      
    
     Nitroimidazole is considered clearly hepatotoxic, renal toxic with reports of diffused damage 
of parenchymal and nonparenchymal liver cells as initial stage of hepatic damage using electron 
microscopy and biochemical markers in serum with emphasis of pathophysiology [31].  Based 
on evidences of the previous reports on nitroimidazole action of cytotoxicity, oxygen depletion 
(hypoxia),  radiosensitization,  the  present  study  proposed  a  ‘hepatocellular  hypoxia  criteria’ 
assuming that initially liver  cells  loose metabolic integrity  (ATP and NADPH insufficiency 
from glucose to cause oxygen insufficiency in mitochondria) and undergoes apoptosis followed 
by detectable necrosis in liver. Our previous observation on nitroimidazole effect on hepatic 
amoebiasis  and  amoebic  abscess  development  indicated  the  possibility  of  nitroimidazole 
concentration dependence with oxygen depletion, nitric oxide production, cytokine synergy and 
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liver cell enzyme alterations as inter-related consequences of liver regeneration [32].  The major 
players were the energy metabolizing and lysosomal enzymes as initial liver damage. Using this 
information,  the liver  cell  enzyme profile  was designed to define the hypoxia sensitivity of 
nitroimidazole by ‘Hepatocellular  Hypoxia Criteria’.   The novelty of hepatocellular  hypoxia 
criteria was the detailed cytomorphic-biochemical information using altered enzyme activities 
during initial cytomorphic changes in hypoxic hepatic cells by electron microscopy to confirm 
the  role  of  cell  organelle  in  hypoxia  development.   The  criterion  can  be  used  to  evaluate 
common liver  hypoxia  conditions  such as  hepatic  tumors,  hepatic  infections.  However,  the 
possibility of various hepatocytoxicity mechanisms was reported as initial loss of metabolic 
integrity  in experimental  animal  models exposed to  nitroimidazole derivatives.  Several  new 
nitroimidazole derivatives are emerging as potential cancer chemosensitizers, hypoxia markers 
and hypoxia imaging contrast agents [32-36].  Such ongoing developments need the clear and 
complete  information  on  action  of  new  nitroimidazole  derivatives  in  tumor  selective 
cytotoxicity, oxygen depletion and hepatocellular DNA and enzyme alterations before they can 
be  used  in  hypoxia  monitoring  and  therapy.  Further  we  believe  that  initially  glucose  and 
calcium hemostasis are the primary targets of hepatic hypoxia followed by induced metabolic 
integrity  loss  leading  to  apoptosis  and  regulatory  failure  in  glycolytic,  TCA  cycle, 
gluconeogenesis and Ca++ mediated cAMP related biodegradation of molecules [31].  
Hepatocellular Hypoxia Criteria:  The criterion was a step by step sequence of hepatocellular 
damage: 1. initial loss of metabolic integrity; 2. programmed regulatory failure of cell oxygen 
and energy metabolism; 3. liver tissue inflammation and immunity loss; 4. necrosis and active 
death. The purpose of metabolic integrity in hepatocytes is keep intact by maintaining balance 
between glucose formation and glucose breakdown to maintain energy flow of NADPH and 
ATP molecules. Sequence: The nitroimidazole induced liver cell cytotoxicity leads to enhanced 
glucose breakdown and more demand of ATP and NADPH. With course of time, high energy 
demand at the cost of cell metabolic resources leads to metabolic integrity loss or energy loss 
and oxygen deprivation followed by possibility of step by step programmed cell death (only in 
tumor cells). In normal liver cells, the nitroimidazole cytotoxicity effect cause less damage and 
cells sustain the effect while struggling oxygen starved infected or tumor cells further loose 
capability  to  stay  alive  (such  cells  die  after  nitroimidazole  induced  infected  or  tumor  cell 
killing). In normal cells, liver regeneration recovers the damage. 
In the present study, the hepatic hypoxia criterion focus was on 3 major components: 1. Major 
event of high glycolytic rate is immediate result of high glucose turnover such as glycolysis 
followed  by  secondary  metabolic  cycles  viz.  tricarboxylic  acid,  glycogenolysis, 
gluconeogenesis,  pentose phosphate  pathways  due  to  energy  loss;  2.  Changes  in  peripheral 
biomarkers such as cytokine immunity, altered glutathione reductase, nitric oxide production, 
super oxide dismutase enzymes (data not shown); 3. Severe energy loss and oxygen depletion 
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results with changes in liver cellular morphology and tissue shrinkage. The study highlights the 
sensitivity  of  different  enzymes  as  response  of  nitroimidazole  induced  cytotoxicity.  We 
proposed a simple scheme of “Hepatocellular Hypoxia Criteria” as shown in Table 1.
Origin of hypoxia: Oxygen insufficiency or hypoxia begins with low NADPH and ATP supply 
from glucose. Glucokinase, aldolase, pyruvate kinase and lactate dehydrogenase possibly serve 
as initial glycolytic regulatory enzymes for  energy flow to generate tricarboxylic  acid cycle 
(TCA)  precursors.  TCA  cycle  being  as  source  of  energy  molecule  synthesis  and 
gluconeogenesis it serves mainly as available central ATP control tool of glucose homeostasis 
in  liver  cytototoxicity  or  regenerated  liver  cell  [37,  38].  The  citrate  synthase,  malate 
dehydrogenase, isocitrate dehydrogenase and succinate dehydrogenase enzymes serve as TCA 
cycle regulatory enzymes. These enzymes in hepatocytes likely define the nature of hepatocyte 
tumor hypoxia and hepatocyte response after nitroimidazole therapy [37, 38, 39]. At the cost of 
ATP from TCA cycle and oxygen from cell,  oxidative phosphorylation maintains metabolic 
integrity  and continuous flow of  energy.  In  the  state  of  low NADPH and low oxygen cell 
undergoes  state  of  metabolic  integrity  loss  and  “hypoxia”.  NADPH dependent  cytochrome 
redox  enzymes  are  indicator  of  oxidative  phosphorylation  status  and  oxygen  insufficiency 
(hypoxia)  in  liver.   Other  glutathione  reductase  and  superoxide  dismutase  enzymes  are 
indicators of hypoxic state of liver cells [2, 26, 40, 41]. Any energy imbalance and oxygen 
insufficiency (hypoxia) in liver cell are indicated by these enzymes. 
Table 1: A step by step scheme of “hepatocellular hypoxia criteria” to evaluate liver hypoxia damage in 
infected hepatitis or hepatic tumors. Different clinical methods suggest composite picture of hepatic hypoxia 
and associated biochemical and cytomorphic changes (shown highlighted in yellow).
                                                
Morphological changes                       Clinical changes                    Liver biochemical changes
_____________________________________________________________________________
1. Physical examination:          
        --                                                   abdominal pain                                    --
       intestinal damage                           fever                                                    --
       hepatic infiltration                         hepatomegaly                       liver function tests(elevated)
                                                  Loss of cellular metabolic integrity
2.Electron microscopy:                         hepatomegaly with           altered hepatocyte enzymes of: 
Mitochondria(M)                         diffused injury             low ATP/ADP; NADPH/NADP 
endoplasmic reticulum(ER)                                                      gluconeogenesis
peroxisome (P)                                                                         glycogenolysis
lysosome (L)                                                                             lysosomal enzymes
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nuclear changes (N)                                                                 oxygen flux related 
                                               Hepatocellular enlargement (Apoptosis)
3. Cellular organelle damage:            poor drug response                 slow metabolic disorder:
         mitochondria(M)                                                                     oxidative phosphorylation
         microsomes (MI)                                                                      drug metabolizing enzymes
         lysosome (L)                                                                             initial phagocytosis 
         nuclear (N)                                                                                DNA fragmentation(beads) 
         cytosol (C)                                                                                glucose/protein/respiratory 
                                                                                                            burst
                                      Hepatocellular Oxygen insufficiency (inflammation)
4. Liver pathology changes:            raised diaphragm                        
    mitochondrial damage                 amebic liver scan +ve            stimulation of Kupffer cells
    exfoliative ER                                                                              hyperplasia of Kupffer cells
    anisonucleosis                                                                                  loss of metabolic control
    autophagy & lysosomal irritation                                                    increased water accumulation 
    cytosolic granulation                                                                       increased molecule  imbalance 
    fatty liver appearance with                                                              increased lipid synthesis
    membrane damage 
                                               Hepatocellular degeneration and necrosis
5. Hepatocytology:
    Cell proliferation                 advancing tumor vascularization         surgical aspirates (altered 
    Cell debris                               tissue growth on ultrasound             proteins, lipids, enzymes)
                                        
                                          Nitroimidazole single dose therapy schedule
6. Liver cell recovery               negative liver scan/ultrasound          normal liver function test 
    Tissue shrinkage                   Hypoxia monitoring negative          -ve Hypoxia biomarkers 
                                       OR       if unchanged or poor recovery           abnormal ELISA,enzymes 
                                                                         
                                                             Surgical intervention
Origin of hypoxia: Glucokinase, aldolase, pyruvate kinase and lactate dehydrogenase possibly 
serve as initial  glycolytic regulatory enzymes for energy flow to generate  tricarboxylic acid 
cycle(TCA)  precursors.  TCA  cycle  being  as  source  of  energy  molecule  synthesis  and 
gluconeogenesis it serves mainly as available central ATP control tool of glucose homeostasis 
in  liver  cytototoxicity  or  regenerated  liver  cell  [37,  38].  The  citrate  synthase,  malate 
dehydrogenase, isocitrate dehydrogenase and succinate dehydrogenase enzymes serve as TCA 
cycle regulatory enzymes. These enzymes in hepatocytes likely define the nature of hepatocyte 
tumor hypoxia and hepatocyte response after nitroimidazole therapy [37, 38, 39]. At the cost of 
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ATP from TCA cycle and oxygen from cell,  oxidative phosphorylation maintains metabolic 
integrity  and continuous flow of  energy.  In  the  state  of  low NADPH and low oxygen cell 
undergoes  state  of  metabolic  integrity  loss  and  “hypoxia”.  NADPH dependent  cytochrome 
redox  enzymes  are  indicator  of  oxidative  phosphorylation  status  and  oxygen  insufficiency 
(hypoxia)  in  liver.   Other  glutathione  reductase  and  superoxide  dismutase  enzymes  are 
indicators of hypoxic state of liver cells [2, 26, 40, 41]. Any energy imbalance and oxygen 
insufficiency (hypoxia) in liver cell are indicated by these enzymes. 
  
In  present  study,  emphasis  has  been  concentrated  only  upon  2’-nitroimidazole  induced 
carbohydrate  metabolizing  enzymes  and  description  of  nitroimidazole  induced  oxygen 
deprivation by ‘hepatocellular hypoxia criteria’.   Based on this approach nitroimidazole was 
evaluated for its safe antiparasitic or anticancer drug value and liver cells’ oxygen depletion in 
liver  cells  (nitroimidazole  tumor  therapy).   Earlier  studies  also  reported  nitroimidazole 
evaluation by its oxygen deprivation action, cytotoxicity action and antiparasitic action [1-30]. 
The paucity of information on nitroimidazole-liver tissue interaction can be predicted partly by 
data of initial sequential  biochemical changes in liver cells which further  lead to detectable 
hypoxia  [43].  The  novelty  of  representative  serum  enzyme  measurement  was  to  establish 
‘hepatocellular hypoxia criteria’ as hypoxia biomarker of nitroimidazole therapeutic evaluation 
and hepatic regeneration if any. The hypoxia is a sequence of initial energy loss and oxygen 
insufficiency  leading  to  apoptosis  and  organelle  changes.  The  major  finding  was  that 
carbohydrate  metabolizing enzymes showed metabolic integrity  loss in hepatocyte cells and 
oxygen depletion after  nitroimidazole  treatment.  The serum enzyme profile  serves  as quick 
hypoxia assessment.
Methods and Materials
Patients: In 10 control subjects, stool, ELISA, serum and liver biopsies were collected2. Only 
proved 10 subjects free from any hepatic disease were examined for enzyme estimations in 
isolated liver cells from biopsy specimens.  Other ten subjects were treated with nitroimidazole 
(Tiniba and Zil from Hindustan Lever Ltd, Bombay) therapy 2 x 5 gm one-time dose thrice at 2 
days interval.  At the end of dose, liver biopsy and serum collection was done.  The ELISA was 
done by method of Prakash et al.[44].  Liver biopsy was taken by Manghini needle [45]. 
Biochemical assays: In biopsy sonipreps and serum samples the hepatocellular enzymes were 
estimated as described elsewhere [46].  All substrates of enzymes were obtained from Sigma 
2
 The patients were studied for ongoing other research study on amoebic hepatitis vs amoebic liver abscess by 
Hepatocellular Dysfunction Criteria at Liver Unit, AIIMS. The results of hepatic damage are shown in Figure 
3. 
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Chemical Company, St Louis,  USA.  The estimations were done on UV spectrophotometer 
Cecil Inc. England [46].  
Electron microscopy:  The biopsy specimens at stored in glutaraldehyde at -20°C. For fixing 
samples were fixed in dental wax and immersed in pool of 0.1 M phosphate buffer containing 
0.1 M Ca++. The samples were cut 1 mm cube by Gillette blade. The cubes were fixed for 2 
hours in 0.2 M phosphate buffer in 4 changes at 30 minutes interval in capped vials. The vials 
were washed for 2 hours in 0.2 M phosphate buffer 4 times at 30 minutes interval in capped 
vials.  The  vials  were  post  fixed  in  buffered  1%  osmium  tetroxide  for  1-2  hours  at  4°C, 
dehydrated in cold 10% ethanol for about 5 minutes followed by dehydrations in cold 50%, 
70%, 80%, 95% ethanol for about 5 minutes each and tissues were kept at room temperature. 
Further  tissues were dehydrated at  100% ethanol for  15 minutes.   Electron Microscope PA 
model was used for screening hepatic cell damage by epoxy resin blocks and osmium tetra 
oxide staining [46].
Results
All the 10 control subjects had no clinical findings of any hepatic disease and showed stool -ve, 
ELISA -ve.  All 10 showed normal liver and no abscess confirmed by ultrasound and liver scan. 
The subjects were selected of 35 + 15 years (mean age + sd), average monthly income 1750 + 
100  INR,  no  hepatomegaly,  no  diarrhea,  fever  and  pain.  The  subjects  after  nitroimidazole 
treatment  showed  induced  hepatomegaly  insignificant  less  than  2  cm  by  liver  scan.   The 
subjects with amoebiasis and amoebic liver abscess are not included and not shown here.
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Figure 2: The liver scan (on left panel) is shown for assessing the position of hepatic hypoxia 
and associated hepatomegaly and for biopsy collection site as shown with arrow.
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Figure 3: The histogram bars show the effect of nitroimidazole on biomarker enzymes and comparison 
of different enzymes in hepatocytes and Kupffer cells in control vs nitroimidazole treated subjects (panel 
on top and bottom)
Figure 3(continued)
Figure 3: The histogram bars show the effect of nitroimidazole on biomarker enzymes and comparison 
of different enzymes in serum biomarker enzymes. 
Initial loss of metabolic integrity of glycolysis and ATP:
In serum and liver cells of these subjects, exhibited more or less specific characteristic changes 
in enzymes.  In nitroimidazole treated subjects the glucokinase levels were more or less normal 
in both serum and biopsy (100%).  In nitroimidazole treated subjects the phosphofructokinase 
levels were nonspecific. In nitroimidazole treated subjects the levels were normal (80%).  In 
nitroimidazole treated subjects the lactate dehydrogenase levels were reversed to normal.  In 
nitroimidazole treated subjects the levels were normal (100%).  In nitroimidazole subjects, the 
levels  were  normal  (80 %).  In  nitroimidazole  treated  subjects,  the  isocitrate  dehydrogenase 
enzyme levels  were  normal  (80 %) in  serum.  In nitroimidazole  treated subjects,  the citrate 
synthase  levels  were  normal.  In  nitroimidazole  treated  subjects,  the  phosphogluconate 
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dehydrogenase  levels  were  normal  (80  %)  in  both.  In  nitroimidazole  treated  subjects,  the 
succinate dehydrogenase levels were normal (60 %) in both. The enzymes are shown in Figure 
3 and Tables 2-4.
  
Figure  4:  Ultrastructural  changes  are  shown  in  hepatocyte  organelles  during  hypoxia:  exfoliation  of  endoplasmic 
reticulum (top on left);  anisonucleosis  (mid and bottom on left);  intercellular  junction gaps (top and mid panels  in 
center); nuclear inclusions (bottom on center); swollen and bizarre mitochondria (top on right); inclusions in peroxisome 
(mid on right); mitochondrial atrophy with lipid vesicles (bottom on right).
Hypoxia marker enzymes and Kupffer cell lysosomal enzymes:
 
In nitroimidazole treated subjects, the -glucuronidase levels were normal (50 %) in Kupfferβ  
cells and also normal in serum (60%).  In nitroimidazole treated subjects, the acid phosphatase 
levels were normal in both.  In nitroimidazole treated subjects, the levels were normal in serum 
(80 %) and remained high in Kupffer cells (60%). In nitroimidazole treated subjects, the levels 
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were normal in both Kupffer cells and serum (80%). The enzymes are shown in Figure 2 and 
Table 3.
The ultrastructure of liver cells showed characteristic changes in nitroimidazole exposed liver. 
Hepatocyte mitochondria  became swollen,  bizarre  with dense matrix  and showed destroyed 
cristae,  endoplasmic  reticulum  dilated  vesicles,  giant  nuclei  with  diffuse  proliferation  of 
endoplasmic reticulum and clear anisonucleosis features. Kupffer cell hyperplasia was observed 
with swollen lysosomal contents as shown in Figure 4.
In  above,  altered  glycolytic  enzymes  in  cytosol,  TCA  cycle  enzymes  in  mitochondria, 
lysosomes and increased synthesis of enzymes by endoplasmic reticulum showed correlation 
with clear liver cell degeneration of microbodies.   After nitroimidazole treatment, observations 
of both electron microscopy and biochemical parameters suggested the reversed hepatocellular 
changes towards normal recovery.
Discussion
The liver is made of parenchymal hepatocytes and nonparenchymal Kupffer cells as sole targets 
that exhibit their intracellular biochemical changes. The enzyme biomarkers could be analyzed 
in  serum  and  hepatocytes  as  clinically  significant  indicator  of  hepatic  damage.  In  hepatic 
cytotoxicity,  initially  metabolic  integrity  loss  leads  to  oversecretion  of  liver  cell  enzymes 
including lysosomal enzymes. Soon after, the ultrastructural changes in liver cells by electron 
microscopically are suggestive of acute organelle degeneration.
It was evident that ultrastructural parenchymal cytotoxicity was associated with nitroimidazole 
overdosage (normal dosage is 2 x 3 gm one time in amoebic hepatitis and thrice in amoebic 
abscess). The regenerative change consistently observed after nitroimidazole therapy to reverse 
liver damage.  Few pathology reports are available to show nitroimidazole cytotoxicity and no 
electron microscopy study is available as unequivocal diffuse parenchymal injury exhibiting 
diffused  sinusoidal  and  portal  infiltration  events  [47,  48,  49].   Still  such  changes  may  be 
misleading  as  these  can  be  expected  to  occur  in  any  other  inflammatory  disease  of  liver 
associated with negative symptoms.  So, in present study, biomarker  enzymes with electron 
microscopy evidence of cytotoxicity in liver biopsy samples after nitroimidazole treatment are 
evidenced by possible hepatic hypoxia criteria.
Degenerative changes of hepatocytes were consistently observed suggestive of necrosis.   At 
maximum, these conditions were excluded among the present control group of subjects.  
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Evidence  of  hepatic  regenerative  reaction  and nitroimidazole  cytotoxicity  (hypoxia  induced 
changes) was characterized by cytokine synergy, unusual degree of anisonucleosis, nitric oxide 
production and the presence of giant nucleus in hepatocytes after  liver  regenerative therapy 
[50].  Endoplasmic reticulum showed a diffuse and intense proliferative activity in these liver 
cells  with  normal  appearance  of  mitochondria  as  earlier  reported  [47,  48,  49].   However, 
intramitochondrial inclusion bodies were absent but they have been reported as very prominent 
features  [47].    The cause of the ultrastructural  changes after  nitroimidazole cytotoxicity as 
shown in this study can be supported by initial enzyme alterations reflecting loss of metabolic 
integrity  probably  induced  by  free  radical  formation  from  nitroimidazole  [30].    Since 
ultrastructural changes in liver were completely reversible after nitroimidazole therapy within 
7-9 days, it  is quite reasonable that pathogenesis of diffused hepatocyte damage was due to 
nitroimidazole breakdown products as reported earlier [30].
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
73
8.
1 
: P
os
te
d 
30
 D
ec
 2
00
8
Figure 5: The sketch of nitroimidazole induced intracellular enzymes changes indicating the points of metabolism and 
metabolic control during hypoxia and subsequent liver recovery after nitroimidazole treatment . The enzymes distribution 
in  organelle  and  enzyme  location  in  different  hepatic  sites  explains  the  liver  damage  and  enzymatic  basis  of 
hepatocellular hypoxia criteria [reproduced from Sharma R. Ph.D dissertation].
   The ‘Hepatocellular hypoxia criteria’ was proposed as a sequence of events of hepatic cell 
injury at molecular level. The initial loss of hepatocellular metabolic integrity leads to hepatic 
injury.    Glucose-energy  metabolic  integrity  loss  and  nitric  oxide  formation  with  Ca++ 
homeostasis  have  been  cited  as  main  initial  determinants  of  hypoxia  [51].    Present  study 
addressed  the  question  of  glucose  metabolizing  pathways  viz.  glycolysis,  TCA  cycle  and 
gluconeogenesis.    In hepatic cells,  metabolic alterations of these pathways in hepatitis and 
hepatic tumors are best correlated with respective enzymes and ultrastructural changes in cells. 
The following description is broad explanation of different enzymes secreted from hepatocytes 
as  a  result  of  nitroimidazole  induced cytotoxicity  and  oxygen depletion.  Form biochemical 
stand  point,  different  regulatory  enzymes  are  discussed  as  biochemical  events  of  hypoxia 
development as shown in Figures 3 and 4.
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Figure 4: The sketch of relative biomarker enzyme changes (as arrow thickness) in liver due to nitroimidazole 
effect. The +ve sign denotes the relative increase in enzyme activity and –ve sign denotes the decrease in enzyme 
activity in liver cells in different organelles. The figure sketch also represents a sequence of metabolic steps of 
hepatocellular hypoxia criteria [Reproduced from Sharma R. Ph.D dissertation].
Role of enzymes in energy metabolic integrity in hypoxia    
    Hexokinase, a rate limiting enzyme in cytosol for glucose turnover was estimated due to high 
glucose  conversion  into  glucose  6P  showed  high  enzyme  secretion  from  hepatocytes. 
Aldolase,  rate  controlling  enzyme  which  splits  fructose-1,  6  Diphosphate  into  two  3- 
phosphoglyceric acid and dehydroxyacetone phosphate, showed high enzyme secretion from 
heptocytes.   Phosphofructokinase, rate controlling enzyme which phosphorylates fructose 6P 
into fructose 1, 6 DiP, enhanced as its more demand in hepatocellular glucose turnover which 
probably  induced  higher  secretion  of  phosphofructokinase.    Pyruvate  kinase,  transferring 
phosphoryl group from phosphoenolpyruvate to ADP with pyruvate formation,  showed high 
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enzyme secretion from hepatocytes. It may be attributed due to high concentration of glycolytic 
intermediates  as  terminal  step  was  blocked  or  due  to  2,  3  Di-Phosphoglycerate  regulated 
abnormal oxygen dissociation.   Malate dehydrogenase and isocitrate dehydrogenase enzymes, 
catalyzing malate oxidation into oxaloacetate and oxidative decarboxylation of isocitrate into 
-ketoglutarate respectively both require NADα +. Both enzymes were elevated in damaged cells 
due to reducing equivalent low ratio of NADH/NAD+ pushing in forward direction.   Succinate 
dehydrogenase, oxidizing succinate to fumerate using FAD, showed decreased enzyme levels 
due  to  low iron  sulphur  proteins  resulting  with  lowered  electron  transport  system in  inner 
mitochondrial membrane i.e. supply of electrons to molecular oxygen by electron transfer from 
FADH2 to Fe+++ (SDH) in amoebic recruited liver cells.   Citrate synthase, synthesizing citrate 
from  oxaloacetate  and  acetyl  CoA  by  aldol  condensation  followed  by  hydrolysis,  showed 
elevated  levels  due  to  rapid  turnover  of  oxaloacetate  and  acetyl  CoA  molecules  during 
cytolysis.   Moreover, high TCA cycle activity in hepatocyte during liver damage conditions 
was  described  earlier  [1].   In  serum,  the  enzymes  exhibit  their  significance  but  aldolase, 
pyruvate  kinase  and  LDH,  MDH,  ICDH observed  as  distinguishing  the  diffused  injury  or 
abscess formation [52].   Phosphogluconate dehydrogenase elevated levels may be attributed 
due to ribulose 5P formation and transaldolase and transketolase control, for phosphogluconate 
pathway.   Nitroimidazole  induced  cytotoxicity  perhaps  have  insignificant  impact  on  ATP 
supply.
     Hypoxia is represented as a state of oxygen depletion in cell. Initially liver cell gets ATP and 
NADPH  supply  from  glycolysis  and  TCA  cycle.  Consequently,  electron  transfer 
chain(oxidative  phosphorylation)  through  series  of  cytochrome  redox  reactions  converts 
available cell oxygen to water to make high energy metabolites in the cell (metabolic integrity). 
Infected  liver  cells  and  tumor  cells  already  have  less  available  oxygen  (oxygen  starved). 
Nitroimidazole cytotoxicity was established two decades ago as potential oxygen quenching 
chemical  in  most  of  the  infected  and  tumor  cells.  Here  the  fact  “Nitroimidazole  oxygen 
quenching actions makes oxygen starved cells further worse to die and leaving normal cells 
functional” can be observed as potential tumor hypoxia therapy and antiparasitic treatment by 
nitroimidazole. 
    During metabolic integrity loss and resultant hypoxia state, liver cell signals the alarm to 
produce nitric oxide, release of cytokines (IFN-γ with IL-1β or TNF-α).  These changes trigger 
the sequence of Kupffer cell stimulation and lysosomal action.  As a result, lysosomal enzymes, 
growth factor, plasminogen stimulating factor were consistently observed suggestive of Kupffer 
cell  suicidal  phagocytic  action  (hepatic  necrosis)  by  nitroimidazole  analogs  and  reviewed 
widely  [32,  50].    In  drug  induced hepatitis,  liver  lysosomal  enzymes  have  been  reported 
elevated or stimulation for any cellular defense apart from respiratory burst and chemotaxis by 
liver cells [53].  The present study showed the associated electron microscopic observations that 
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Kupffer  cells  accumulate  around  and  exhibited  hyperplasia  condition  showing  degenerated 
nucleus, enlarged lysosomal vesicles.  The enlarged lysosomal vesicles were further correlated 
by higher lysosomal enzyme levels in serum.   In liver biopsies these lysosomal enzymes were 
significantly  enhanced  as  shown  in  Table  2-3.   Acid  phosphatase,  leucine  aminopeptidase 
enzymes catalyzing phosphorylation and amino-peptidization,  seem to be secreted more and 
suggestive of active protein degradation.  -glucuronidase and aryl sulphatase high enzymeβ  
secretion was suggestive of continuous breakdown of aryl substituted and -glucuronidationβ  
reactions during cytolysis [54]. No data is available on liver cell enzymes estimated in liver 
cells from liver biopsy of nitroimidazole treated livers.  Liver  cell enzymes may expand the 
better biochemical explanation of complex hypoxia state at molecular level. However, several 
scattered studies on serum choline esterase, alkaline phosphatase, glucose-6P-dehydrogenase, 
ornithine carbamoyl transferase, cyclooxygenase2, lactate dehydrogenase enzymes have been 
reported  significant  in  hepatic  hypoxia  or  hepatic  damage evaluation  with  addition  of  new 
members of enzymes [54-56].   
    There appear two main reasons of enzyme level recovery by nitroimidazole.  First, these 
enzyme changes were recovered by nitroimidazole therapy as drug changes the energy status in 
heaptocytes and Kupffer cell macrophagal activity diminishes the hepatic enzyme secretion and 
results in decreased enzyme levels towards normal.   Second, regenerating hepatocytes may also 
regulate  the normal cell recovery process and initializes the signaling Kupffer cells to keep 
stored enough lysosomal enzymes.
Challenges, Limitations and Futuristic approaches
 
There are two major challenges. First challenge was to get enough biopsy to estimate several 
enzymes.  Second  challenge  was  to  choose  significant  enzymes  as  representative  of 
hepatocellular criteria. The main limitation was that the ‘hepatocellular hypoxia criteria’ was 
used  in  small  number  of  human  subjects.  The  biopsy  samples  for  electron  microscopy 
observations  needs  more  thoroughly  controlled  experiments.  Other  limitation  was  that  the 
enzyme estimations in serum and biopsy samples may not be perfect representative samples and 
it needs to establish the measurable and actual enzyme activities in cells. The most crucial issue 
is  that  hypoxia  is  a  combination  of  sequence  of  several  metabolic  and  subphysiological 
reactions in cells. Moreover, other inflammatory cytokines, apoptosis, nitric oxide production 
and phagocytosis are associated changes during hypoxia. It further needs tracer technique to 
track  the details  of  hypoxia  in  cell.  In  future,  chip technology or  silica  or  polymer  coated 
enzyme estimation  techniques  may be  more  reliable  in  small  sample  collections  with  high 
degree of accurate enzyme estimation.  
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Conclusion
The 2’nitroimidazole is both antiaparasitic drug and radiosensitizer hypoxia marker in tumor 
therapy.  It  shows  hepatocellular  cytotoxicity.  The  ‘hepatocellular  hypoxia  criterion’ 
distinguishes  the  nitroimidazole  induced  hepatocellular  oxygen  depletion  and  associated 
organelle  changes  by  enzyme  levels  in  serum,  enzyme  levels  in  biopsy  samples  and  cell 
organelles by electron microscopy. Initially, glucose regulation leads to metabolic integrity loss. 
Later, it may be oxygen insufficiency and slow cell death.  The 2’-nitroimidazole is drug of 
choice in hepatic infections and its  derivatives  are  emerging  choice of tumor treatment.  Its 
action may be evaluated rapidly by enzyme biochemical estimations without time consuming 
drug monitoring and therapeutic assay techniques.
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